The company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- RIGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib
- Rigel Pharmaceuticals sees Q4 revenue $57.6M, consensus $47.42M
- Rigel Pharmaceuticals sees FY25 revenue $200M-$210M, consensus $193.51M
- Rigel announces R289 granted Orphan Drug designation by FDA for MDS